79128-70-4

Usage

Uses

Used in Pharmaceutical Research and Development:
METHYL 3-(BENZOYLAMINO)-2-THIOPHENECARBOXYLATE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the creation of novel drugs and biologically active molecules. Its structural properties allow for versatile applications in medicinal chemistry, enhancing the development of new therapeutic agents.
Used in Organic Synthesis:
In the field of organic chemistry, METHYL 3-(BENZOYLAMINO)-2-THIOPHENECARBOXYLATE serves as a crucial building block, facilitating the synthesis of complex organic compounds. Its presence in reactions can lead to the formation of a variety of chemical entities, broadening the scope of organic synthesis.
Used in Agrochemical Production:
METHYL 3-(BENZOYLAMINO)-2-THIOPHENECARBOXYLATE is also utilized as an intermediate in the production of agrochemicals, where it plays a role in the development of new pesticides or other agricultural chemicals. Its contribution to this field is significant for enhancing crop protection and management strategies.

InChI:InChI=1/C13H11NO3S/c1-17-13(16)11-10(7-8-18-11)14-12(15)9-5-3-2-4-6-9/h2-8H,1H3,(H,14,15)

Upstream product

• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 618-32-6 Benzoyl bromide 
• 98-88-4 benzoyl chloride 

Downstream Products

• 158715-04-9 3-benzoylaminothiophene-2-carboxamide 
• 18678-14-3 2-phenyl-3H-thieno[3,2-d]pyrimidin-4-one 
• 79128-75-9 N-Thiophen-3-yl-benzamide 

Relevant academic research and scientific papers

Chemical Space Exploration around Thieno[3,2- d]pyrimidin-4(3 H)-one Scaffold Led to a Novel Class of Highly Active Clostridium difficile Inhibitors

Clostridium difficile infection (CDI) is the leading cause of healthcare-associated infection in the United States. Therefore, development of novel treatments for CDI is a high priority. Toward this goal, we began in vitro screening of a structurally diverse in-house library of 67 compounds against two pathogenic C. difficile strains (ATCC BAA 1870 and ATCC 43255), which yielded a hit compound, 2-methyl-8-nitroquinazolin-4(3H)-one (2) with moderate potency (MIC = 312/156 μM). Optimization of 2 gave lead compound 6a (2-methyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one) with improved potency (MIC = 19/38 μM), selectivity over normal gut microflora, CC50s > 606 μM against mammalian cell lines, and acceptable stability in simulated gastric and intestinal fluid. Further optimization of 6a at C2-, N3-, C4-, and C7-positions resulted in a library of >50 compounds with MICs ranging from 3 to 800 μM against clinical isolates of C. difficile. Compound 8f (MIC = 3/6 μM) was identified as a promising lead for further optimization.

Direct metallation of thienopyrimidines using a mixed lithium-cadmium base and antitumor activity of functionalized derivatives

A series of thieno[2,3-d]- and thieno[3,2-d]pyrimidines have been easily synthesized using as key step a deproto-cadmiation-trapping sequence. Some of the compounds thus synthesized were screened for anticancer (cytotoxic) activities, and (S)-2-(6-iodo-2-